Organon & Co.
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
OGN$13.89+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
($ in millions)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash Flows from Operating Activities | |||
| Net income | $864 | $1,023 | $917 |
| Adjustments to reconcile net income to net cash flows provided by operating activities: | |||
| Depreciation | 132 | 120 | 96 |
| Amortization | 145 | 116 | 116 |
| Impairment of assets | — | — | 9 |
| Acquired in-process research and development and milestones | 81 | 8 | 107 |
| Fair value changes in contingent consideration | 11 | — | — |
| Deferred income tax benefit | (160) | (485) | (18) |
| Stock-based compensation | 105 | 101 | 75 |
| Unrealized foreign exchange (gain) loss | (2) | 40 | (18) |
| Other | 41 | 31 | 26 |
| Net changes in assets and liabilities, net of assets acquired | |||
| Accounts receivable | 383 | (212) | (123) |
| Inventories | (131) | (230) | (220) |
| Other current assets | (236) | (10) | (43) |
| Trade accounts payable | (157) | 163 | (237) |
| Accrued and other current liabilities | (101) | 102 | 172 |
| Income taxes payable | (65) | 16 | 7 |
| Other | 29 | 16 | (8) |
| Net Cash Flows Provided by Operating Activities | 939 | 799 | 858 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (175) | (251) | (196) |
| Proceeds from sale of property, plant and equipment | 4 | 1 | 7 |
| Acquired in-process research and development and milestones | (71) | (8) | (107) |
| Dermavant acquisition, net of cash acquired | (166) | — | — |
| Purchase of product rights and asset acquisition | (105) | (2) | (124) |
| Net Cash Flows Used in Investing Activities | (513) | (260) | (420) |
| Cash Flows from Financing Activities | |||
| Proceeds from debt | 1,186 | 80 | — |
| Repayments of debt | (1,197) | (338) | (108) |
| Payment of long-term debt issuance costs | (38) | — | — |
| Net transfers to Merck & Co., Inc. | — | — | (24) |
| Employee withholding taxes related to stock-based awards | (22) | (17) | (11) |
| Dividend payments | (297) | (294) | (290) |
| Net Cash Flows Used in Financing Activities | (368) | (569) | (433) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (76) | 17 | (36) |
| Net Decrease in Cash and Cash Equivalents | (18) | (13) | (31) |
| Cash and Cash Equivalents, Beginning of Period | 693 | 706 | 737 |
| Cash and Cash Equivalents, End of Period | $675 | $693 | $706 |
-61-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.